Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

By K. Kataoka, Y. Shiraishi, Yohei Takeda, S. Sakata, Misako Matsumoto, S. Nagano, T. Maeda, Y. Nagata, A. Kitanaka, S. Mizuno and 34 more. Nature, 2016

596 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/43de25f9d99629fa0a6883f9382706cd22892870

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Hung
2. J. Hsu
3. Chia‐Wei Li
4. Jong-Ho Cha
5. Li-Chuan Chan

In Oncology

1. S. Rajkumar
2. M. Hung
3. J. Hsu
4. Chia‐Wei Li
5. Jong-Ho Cha
6. Li-Chuan Chan

Citations in the corpus

• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “In addition, some non-CNV changes in the PD-L1 gene, such as deletion of PD-L1 exons, SNP site mutation [185], DNA double strand break [186], and PD-L1 3’ UTR structural variation [187], are emerging as new genetic mechanisms regulating PD-L1 gene expression.”
• Mechanisms controlling PD-L1 expression in cancer (2019, background): “By harnessing the IFN-γ/JAK/STAT1 pathway, PDL1 expressed on cancer cells inactivate cytotoxic T cells and attenuate immunosurveillance in the TME.”
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022, background): “They implicate mutations in genes of the JAK/STAT and RAS/MAPK pathways, epigenetic modifiers (TET2, CREBBP, KMT2D), and immune checkpoint molecules CD274 (PD-L1)/PDCD1LG2 (PD-L2) [220–223] in disease pathogenesis.”
• Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma (2017, result): “Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers.”